Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
5-ARIs Do Not Lower Bladder Cancer Risk
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Intravesical BCG Associated With Lower UTUC Recurrence Risk
Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a study found.
Prognostic Factors Identified in Patients Undergoing UTUC Surgery
Bladder cuff resection improves survival, according to investigators.
Atezolizumab Added to Chemo Delays Metastatic Bladder Cancer Progression
In a phase 3 trial, atezolizumab plus platinum-based chemotherapy as first-line treatment for metastatic urothelial carcinoma improved progression-free survival vs chemotherapy alone.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Neoadjuvant Chemo Possibly a Better Option in High-Grade UTUC Cases
Patients with high-grade upper tract urothelial carcinoma who respond to neoadjuvant chemotherapy have a reduced risk of death following surgery compared with those who receive adjuvant chemotherapy, a study found.
Jelmyto Approved for Low-Grade Upper Tract Urothelial Cancer
Jelmyto, an alkylating agent, is administered once weekly via ureteral catheter or nephrostomy tube.
Multifocal Tumors in UTUC Are a Risk Factor for Recurrence
In a study, patients who had upper tract urothelial carcinoma with multifocal tumors had a 40% higher risk for urinary bladder recurrence than those with single tumors.
Mitomycin C May Reduce Urothelial Recurrence Risk in UTUC
In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
Epidural Use in Radical Cystectomy Cases Tied to Worse Perioperative Outcomes
Patients who receive epidural anesthesia at the time of radical cystectomy, compared with those who do not, are more likely to have a myocardial infarction and to be readmitted to a hospital within 30 days following surgery.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
POUT Trial May Lead to New Standard of Care for UTUC
Adjuvant platinum-based chemotherapy for upper tract urothelial carcinoma within 90-days of nephroureterectomy improves disease-free and metastasis-free survival compared with surveillance, a study found.
Want to read more?
Please login or register first to view this content.
